The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors.
Rebecca Sophie Kristeleit
Honoraria - Clovis
Research Funding - Clovis
Geoffrey Shapiro
Research Funding - Clovis
Patricia LoRusso
Research Funding - Clovis
Jeffrey R. Infante
Research Funding - Clovis
Michael Flynn
Research Funding - Clovis
Manish R. Patel
Research Funding - Clovis
Sara M. Tolaney
Research Funding - Clovis
John Frederick Hilton
Research Funding - Clovis
Alan Hilary Calvert
Consultant or Advisory Role - Clovis
Research Funding - Clovis
Heidi Giordano
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Jeffrey D. Isaacson
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Jennifer Borrow
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Andrew R. Allen
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Sarah S. Jaw-Tsai
Employment or Leadership Position - Clovis
Consultant or Advisory Role - Clovis
Stock Ownership - Clovis
Howard A. Burris
Research Funding - Clovis